Promising Longer-Term Biomarker Data from NurOwn Program in ALS: Spotlight on NfL in EAP Extension Cohort

Time: 9:00 am
day: Conference Day One Morning


  • CSF samples were drawn during Phase 3 trial (3 treatments, debamestrocel and Placebo) and in participants who continued into EAP (6 treatments, debamestrocel)
  • Trials enable hypothesis-generating data of the impact on a key marker of neuronal death related to longer-term treatment with an autologous cell therapy and the impact of delayed start to treatment
  • Results to be confirmed in phase 3b trial